GlassScriptPhysician profile
Dominic Brink
NPI 1417486234
$5,931.25
in general payments reported to CMS, 2019-2025
24 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $972 · 2022: $1,257 · 2023: $1,186 · 2024: $2,204 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134 · Travel and Lodging: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.58 |
| Travel and Lodging | $568.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,843.71 | 2021-2024 | Optis, Pressurewire, Xience Skypoint |
| Inari Medical, INC. | $1,273.81 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $321.42 | 2022-2024 | Eluvia, Peripheral Rotalink Plus, Ekosonic |
| Janssen Pharmaceuticals, INC | $278.37 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.52 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $250.00 | 2021-2022 | |
| Cardiva Medical, INC. | $198.35 | 2022-2024 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $194.38 | 2021-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $191.10 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $171.46 | 2022-2025 | Lifevest |
| Shockwave Medical, INC | $146.82 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $141.00 | 2023 | Indigo System |
| Terumo Medical Corporation | $124.27 | 2023-2024 | Angio-Seal, Azur Cx Detachable, Metacross Otw |
| Actelion Pharmaceuticals US, INC. | $93.47 | 2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $78.06 | 2024-2025 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.85 | 2024-2025 | Rybelsus, Ozempic |
| Philips North America LLC | $63.25 | 2022-2025 | Eagle Eye |
| Impulse Dynamics (USA) INC. | $60.34 | 2023 | Optimizer |
| Pfizer INC. | $60.11 | 2025 | |
| Cordis US Corp. | $49.18 | 2023-2024 | Precise Pro Rx, Zephyr, Mynxgrip |
| Chiesi USA, INC. | $20.02 | 2024 | Kengreal, Cleviprex |
| Teleflex LLC | $16.69 | 2024 | Guideliner |
| Convatec INC. | $15.52 | 2024 | |
| Biosense Webster, INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominic Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.